Form 4: Climb Bio SVP of Finance & CAO Reports Routine Stock Transactions for Tax Obligations

Climb Bio, Inc.'s SVP of Finance & CAO, Emily Pimblett, reported the conversion of restricted stock units and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Summary

• Emily Pimblett, SVP, Finance & CAO of Climb Bio, Inc. (CLYM), filed a Form 4 disclosing recent changes in her beneficial ownership.
• On June 18, 2025, 5,000 Restricted Stock Units (RSUs) held by Ms. Pimblett converted into 5,000 shares of the Issuer's Common Stock.
• Following this RSU conversion, Ms. Pimblett's direct beneficial ownership of Common Stock increased to 20,130 shares.
• On June 20, 2025, Ms. Pimblett sold 1,242 shares of Common Stock at a price of $1.24 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Pimblett on April 27, 2024, specifically to cover tax withholding obligations associated with the vesting and settlement of her RSUs.
• After the reported sale, Ms. Pimblett's direct beneficial ownership of Common Stock stands at 18,888 shares.
• Additionally, Ms. Pimblett continues to beneficially own 15,000 Restricted Stock Units.
• The RSUs vest at a rate of 1/8th of the total shares on the three-month anniversary of March 18, 2024, and 1/8th each three-month anniversary thereafter, with full vesting on the two-year anniversary of the March 2024 Vesting Commencement Date.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (RSU vesting and tax-related sale) under a pre-arranged plan. This is a neutral event and does not indicate positive or negative operational performance or strategic shifts for the company.

Future Outlook

The document indicates that the remaining Restricted Stock Units (RSUs) will continue to vest at a rate of 1/8th of the total shares every three months from March 18, 2024, with full vesting expected on the two-year anniversary of that date, provided continuous service to the Issuer.

Industry Context

This Form 4 filing details a routine insider stock transaction, common across publicly traded companies, particularly those that utilize equity compensation like Restricted Stock Units (RSUs) for their executives. The sale to cover tax obligations is a standard practice when RSUs vest, and the use of a Rule 10b5-1 trading plan indicates a pre-arranged, compliant transaction not based on new, non-public information. This type of filing does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transaction represents a routine compensation event for an executive and a minor, expected reduction in direct insider shareholding due to tax-related sales. It does not imply a change in company fundamentals or outlook.
• Employees (specifically Emily Pimblett): The transaction represents the realization of a portion of her equity compensation.

Next Steps

• Continued vesting of remaining 15,000 Restricted Stock Units according to the schedule (1/8th every three months from March 18, 2024, fully vested by March 18, 2026).

Key Dates

Keywords

Climb Bio, CLYM, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, 10b5-1 Plan, Executive Compensation, Emily Pimblett, Beneficial Ownership